Elucid, a pioneer in AI-driven diagnosis, has launched PlaqueIQ, an advanced image analysis tool. This tool takes precise measurements and classifications of atherosclerotic plaque in the carotid arteries.
As the first and only CT-based analysis software manufactured for carotid arteries, PlaqueIQ helps clinicians identify unstable carotid plaques, allowing for personalized treatment plans to reduce the risk of ischemic stroke.
Accurate detection of plaque composition goes far beyond traditional stenosis assessments, enabling better identification of patients at higher stroke risk and improving treatment planning and strategies.
Extending this capability to the carotid arteries is revolutionary. This cutting-edge technology lets us avail ourselves of both the biology as well as structure of carotid plaques, providing a complete view of stroke risk and vascular health, shaping the future of vascular medicine.
This advanced technology is made to assist healthcare providers in prioritizing as well as customizing treatments based not merely on population-derived risk factors but on actual disease characteristics in coronary and carotid arteries.
It improves the ability to assess treatment options based on patients' symptoms and their risk for future events like heart attacks and strokes, helping create personalized care plans tailored to each patient's unique plaque profile.
Executive Statement
According to Dr. Kelly Huang, CEO of Elucid, at Elucid, they are focused on addressing the predominant source of heart attacks and strokes: plaque development, whether present in coronary or carotid arteries. Their aim is to empower physicians with a comprehensive understanding of systemic atherosclerotic risk through a single imaging study, allowing for tailored treatment regimens as well as comprehensive monitoring of the health of a patient.
According to Dr. David Deaton, a noted vascular surgeon and adjunct associate professor at the Perelman School of Medicine, University of Pennsylvania, the capacity to precisely characterize plaque composition fundamentally transforms the assessment of stroke risk associated with carotid arteries.
